BACKGROUND: The aim of this study was to assess the efficacy and safety of pneumatic dilatation (PD) to treat symptom recurrence after Heller myotomy (HM). METHODS: Consecutive patients receiving PD for relapsing symptoms following prior HM were included in this retrospective single-center study. Eckardt score ≤3 and/or ∆ Eckardt (difference between Eckardt score before and after dilatation) ≥3 defined the success of initial dilatation. Patients who maintained response longer than 2 months after initial dilatation were defined as short-term responders. Relapsers were offered further on-demand dilatation. Remission was defined as an Eckardt score ≤3 at the study endpoint. Kaplan-Meier survival curves were used to determine relapse rates. KEY RESULTS: Eighteen patients (11 women, seven men) were included from January 2004 to January 2013. Ten patients had type I achalasia, and seven had type III, according to the Chicago classification. Thirty-nine PDs were performed (1.5 [1-2.25] per patient). All patients had short-term responses. The remission rate at the endpoint, after a median follow-up of 33 months, was 78%, but 44% were treated with on-demand PD during the follow-up interval. The proportions of patients without relapse and subsequent PD were 72% at 12 months, 65% at 24 and 36 months, and 49% at 48 months. No factors predictive of long-term response, particularly the type of achalasia, could be identified in this series. There were no perforations. CONCLUSIONS & INFERENCES: In treating symptom recurrence following HM, PD was safe and effective over the long term when combined with subsequent PD.
BACKGROUND: The aim of this study was to assess the efficacy and safety of pneumatic dilatation (PD) to treat symptom recurrence after Heller myotomy (HM). METHODS: Consecutive patients receiving PD for relapsing symptoms following prior HM were included in this retrospective single-center study. Eckardt score ≤3 and/or ∆ Eckardt (difference between Eckardt score before and after dilatation) ≥3 defined the success of initial dilatation. Patients who maintained response longer than 2 months after initial dilatation were defined as short-term responders. Relapsers were offered further on-demand dilatation. Remission was defined as an Eckardt score ≤3 at the study endpoint. Kaplan-Meier survival curves were used to determine relapse rates. KEY RESULTS: Eighteen patients (11 women, seven men) were included from January 2004 to January 2013. Ten patients had type I achalasia, and seven had type III, according to the Chicago classification. Thirty-nine PDs were performed (1.5 [1-2.25] per patient). All patients had short-term responses. The remission rate at the endpoint, after a median follow-up of 33 months, was 78%, but 44% were treated with on-demand PD during the follow-up interval. The proportions of patients without relapse and subsequent PD were 72% at 12 months, 65% at 24 and 36 months, and 49% at 48 months. No factors predictive of long-term response, particularly the type of achalasia, could be identified in this series. There were no perforations. CONCLUSIONS & INFERENCES: In treating symptom recurrence following HM, PD was safe and effective over the long term when combined with subsequent PD.
Authors: Faisal Kamal; Mohammad K Ismail; Muhammad A Khan; Wade Lee-Smith; Reem Z Sharaiha; Sachit Sharma; Stephanie McDonough; Raseen Tariq; Hemnishil K Marella; Zubair Khan; Rajiv P Heda; Claudio Tombazzi; Colin W Howden; Douglas G Adler Journal: Ann Gastroenterol Date: 2020-12-07
Authors: Sarmed S Sami; Hasan N Haboubi; Yeng Ang; Philip Boger; Pradeep Bhandari; John de Caestecker; Helen Griffiths; Rehan Haidry; Hans-Ulrich Laasch; Praful Patel; Stuart Paterson; Krish Ragunath; Peter Watson; Peter D Siersema; Stephen E Attwood Journal: Gut Date: 2018-02-24 Impact factor: 23.059